Corporate Presentation September 2025 This presentation contains trademarks, service marks, trade names and copyrights of Alumis and other companies which are the property of their respective owners. This presentation discusses product candidates that are under clinical study and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the uses for which they are being studied. This pr ...

Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant DepressionExport of 1,000 natural psilocybin capsules for prescription use under Australia's Authorised Prescriber Scheme follows the Company's successful launch of MDMA sales in 2024September 03, 2025 7:30 AM EDT | Source: Optimi Health Corp.Vancouver, British Columbia--(Newsfile Corp. - September 3, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadia ...

Engagement with Allucent supports NDA pathway and advancement of late-stage gout programCALGARY, Alberta, Sept. 03, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, today announced the initiation of Investigational New Drug (“IND”) preparation for its lead program, XRx-026, focused on the treatment of go ...

BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Tuesday, September 9th at 4:50 PM ET. The live audio webcast of this event, as well as an archived recording, will b ...

白云山9月3日公告，公司控股子公司广州白云山天心制药股份有限公司近日收到国家药品监督管理局核 准签发的《药品补充申请批准通知书》，注射用头孢他啶（0.5g､1.0g）已通过仿制药质量和疗效一致性 评价。注射用头孢他啶为第三代头孢菌素抗生素，适用于治疗敏感微生物引起的单一或多重感染。 ...

Following our summer break, we are resuming coverage of Novartis (NYSE: NVS ) ( OTCPK:NVSEF ). Although Trump enacted a 39% duty on Swiss goods in early August, the measure spares pharmaceuticals, given the USA's reliance on SwissBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, informed as they might be, a ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 肌萎缩侧索硬化症 （ALS） ，也叫做 渐冻症 ，是一种进行性神经退行性疾病，其特征是运动皮层和脊髓中的运动神经元丧失。ALS 和 额颞叶痴呆 （FTD） 最 常见的遗传病因是 C9orf72 基因第一个内含子中 GGGGCC （G 4 C 2 ） 重复序列的扩增。这一扩增促进神经退行性病变的机制尚不清楚，但有研究证据表 明，扩增重复序列的转录和翻译导致了毒性功能增益。正义链 G4C2 或反义链 C4G2 重复 RNA 可以捕获 RNA 结合蛋白，从而破坏其功能。含重复序列的 mRNA 的翻译会产生二肽重复蛋白 （DPR） ，这些蛋白已被证明可通过多种机制发挥毒性作用。 反义寡核苷酸 （ASO） 药物在杜氏肌营养不良 （DMD） 等疾病中获得了成功，受此激励，ASO 已成为 C9orf72 相关肌萎缩侧索硬化症 （c9ALS） 的主要治 疗策略。 BIIB078 是 Biogen 和 Ionis 公司合作开发的一款用于治疗 c9ALS 的 ASO 药物，旨在靶向 C9orf72 基因第一个内含子中的 18 个碱基对序列，并通过 RNase- H 切割降解含 G4C2 重 ...

近日，CDE官网显示，山东新时代药业有限公司按4类化药注册申报的尼可地尔片上市申请申请已获受理。作为上市40余年的经典抗心绞痛药，尼可地尔院 内年销售额超14亿元，"老药翻红"成为新一代"卷王"，并成功入围新国采。 | 受理品种目录浏览 | 在审品种目录浏览 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025 | ▼ | 药品类型: | 全部 | レ 申请类型: | 全部 | ਾ | 童询 | | 请输入受理号 | | 药品名称: | 尼可地尔片 | 企业名称: | 请输入企业名称 | | | | 受理号 CYHS2503128 | | 药品名称 尼可地尔片 | 药品类型 化药 | 申请类型 仿制 | 注册分类 ব | 企业名称 山东新时代药业有限公 司;山东新时代药业有 限公司: | 承办日期 2025-08-26 国际军区 | | 年 会睡着: 序号 | | | | | | | | 截图来源：CDE官网 尼可地尔（Nicorandil）作为一类兼具硝酸酯样作用和ATP敏感性钾通道（KATP）开放作用的双重机制药物，用 ...

Group 1 - The article discusses Zymeworks Inc. (NASDAQ: ZYME) and highlights its recent progress, particularly focusing on two key milestones related to its drug Zanidatamab [2] - The author operates the Biotech Analysis Central service, which provides in-depth analysis of various pharmaceutical companies and includes a model portfolio of small and mid-cap stocks [2] - The service offers a subscription model with a promotional two-week free trial and a discounted annual plan [1] Group 2 - The article does not provide specific financial data or performance metrics for Zymeworks Inc. or its products [4] - There are no disclosures regarding stock positions or business relationships with the companies mentioned, indicating an unbiased perspective [3]

FY25 Results Presentation 3 September 2025 Important notice and disclaimer Rick Ratliff CEO and Managing Director Sean Slattery CFO and Executive Director For personal use only FY25 Results Presentation | © 2025 MedAdvisor Solutions. All rights reserved. This presentation provides general information about MedAdvisor Solutions which is current at the date this presentation is made. This presentation is not a prospectus, product disclosure statement, or any other offering document under Australian law (and w ...